Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;114(9):1547-1555.
doi: 10.1111/add.14655. Epub 2019 Jun 5.

A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder

Henry R Kranzler  1   2 , Richard Feinn  3 , Paige Morris  1 , Emily E Hartwell  1   2
Affiliations
Review

A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder

Henry R Kranzler et al. Addiction. 2019 Sep.

Abstract

Background and aims: Studies of the efficacy of gabapentin for treating alcohol use disorder (AUD) have yielded mixed findings. The aims of our study were to estimate gabapentin's effects on six alcohol-related outcomes, test potential moderators, examine publication bias and evaluate the quality of the studies.

Methods: Meta-analysis of placebo-controlled randomized controlled trials (RCTs). Using PubMed and ClinicalTrials.gov, we selected RCTs of gabapentin's effects on alcohol consumption or a biochemical correlate of it, excluding studies limited to other primary outcomes or that combined gabapentin with other medications. We assessed study quality and used a random-effects model to analyze each outcome measure and the Egger regression test and funnel plots to assess publication bias.

Results: We identified seven RCTs of gabapentin that met study criteria. The quality of the studies overall was good, and there was no evidence of publication bias. Four to seven studies contributed to the analysis of the six outcome measures. For all outcome measures the effect estimates were in a direction that favored gabapentin over placebo. However, only for percentage of heavy drinking days was there good evidence of a benefit (g = -0.64, 95% confidence interval = -1.22 to -0.06).

Conclusions: Although gabapentin appears to be more efficacious than placebo in treating AUD, the only measure on which the analysis clearly favors the active medication is percentage of heavy drinking days. Additional studies are needed to define more clearly the role of gabapentin in AUD treatment.

Keywords: Alcohol use disorder; effect size; gabapentin; meta-analysis; pharmacotherapy; treatment guidelines.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow Diagram of Study Selection
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Food and Drug Administration 2017: Neurontin Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020... (downloaded December 16, 2018).
    1. Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006; 6: 108–13. - PubMed
    1. Roberto M, Varodayan FP. Synaptic targets: Chronic alcohol actions. Neuropharmacology 2017; 122: 85–99. - PMC - PubMed
    1. Leung JG, Hall-Flavin D, Nelson S, Schmidt KA, Schak KM. The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother 2015; 49: 897–906. - PubMed
    1. Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68: 1691–1700. - PubMed

Publication types

Substances